Published May 2020 | Version v1
Journal article

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

Contributors

Others:

Description

Proof of concept studies has reported that circulating endothelial cell (CEC) count may be associated with the outcome of HER2-negative metastatic breast cancer (mBC) patients treated by chemotherapy and the anti-VEGF antibody bevacizumab. We report the results obtained in an independent prospective validation cohort (COMET study, NCT01745757).

Abstract

International audience

Additional details

Identifiers

URL
https://hal.archives-ouvertes.fr/hal-02888436
URN
urn:oai:HAL:hal-02888436v1

Origin repository

Origin repository
UNICA